The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

Unfortunately, the diagnostic and prognostic use of thyroid autoantibody measurements is hampered by technical problems as discussed below. Although autoantibody tests have inherent clinical ...

The U.S. Food and Drug Administration (FDA) has granted Priority Review to Johnson & Johnson’s Biologics License Application ...

House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review ...

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Cabaletta Bio (CABA – Research Report). The company’s ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 Hrs [IST] ...

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...